HC Wainwright set a $6.00 price objective on Fibrocell Science Inc (NASDAQ:FCSC) in a research note released on Wednesday morning. The firm currently has a buy rating on the stock.

Other analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Fibrocell Science from a hold rating to a buy rating and set a $4.25 price objective for the company in a research note on Wednesday, July 12th. ValuEngine upgraded shares of Fibrocell Science from a sell rating to a hold rating in a research note on Thursday, July 20th.

Fibrocell Science (FCSC) traded down 11.55% on Wednesday, reaching $2.68. 106,204 shares of the company’s stock traded hands. Fibrocell Science has a 12-month low of $0.52 and a 12-month high of $4.64. The stock has a 50 day moving average price of $3.61 and a 200 day moving average price of $2.24. The stock’s market cap is $39.38 million.

Fibrocell Science (NASDAQ:FCSC) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31). Fibrocell Science had a negative net margin of 4,307.60% and a negative return on equity of 293.07%. Analysts forecast that Fibrocell Science will post ($1.39) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://theolympiareport.com/2017/08/12/fibrocell-science-inc-fcsc-given-a-6-00-price-target-at-hc-wainwright.html.

Several institutional investors have recently bought and sold shares of FCSC. Renaissance Technologies LLC boosted its position in Fibrocell Science by 272.4% in the fourth quarter. Renaissance Technologies LLC now owns 194,000 shares of the company’s stock valued at $122,000 after buying an additional 141,900 shares in the last quarter. Creative Planning boosted its position in Fibrocell Science by 395.3% in the second quarter. Creative Planning now owns 61,090 shares of the company’s stock valued at $245,000 after buying an additional 48,755 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its position in Fibrocell Science by 264.0% in the second quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock valued at $194,000 after buying an additional 35,000 shares in the last quarter. Hedge funds and other institutional investors own 55.31% of the company’s stock.

About Fibrocell Science

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.